Olema Pharmaceuticals (OLMA) vs Wave Life Sciences (WVE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Olema Pharmaceuticals (OLMA) has outperformed Wave Life Sciences (WVE) over the past year, losing 23.9% versus a loss of 50.8%. Over five years, WVE leads with a -31.3% price change compared with -74.1% for OLMA. Olema Pharmaceuticals is the larger company by market cap ($684.2 million vs $683.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OLMA | WVE |
|---|---|---|
| Share price | $7.82 | $3.47 |
| Market cap | $684.23M | $683.76M |
| 1-day change | -1.51% | -1.98% |
| YTD return | -68.24% | -79.18% |
| 1-year return | -23.95% | -50.76% |
| 5-year return | -74.15% | -31.26% |
| EPS (TTM) | $-2.12 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $36.26 | $21.73 |
| 52-week low | $6.65 | $3.37 |
| Distance from 52-week high | -78.43% | -84.03% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +366.75% | +420.46% |
| Average volume | 1.06M | 3.10M |
| Shares outstanding | 87.50M | 197.05M |
| Employees | 150 | 317 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OLMA has outperformed WVE by 26.8 percentage points over the past year.
About Olema Pharmaceuticals
OLMA stock →Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 150 employees
About Wave Life Sciences
WVE stock →Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
OLMA vs WVE FAQ
Which is bigger, Olema Pharmaceuticals or Wave Life Sciences?
Olema Pharmaceuticals (OLMA) is larger, with a market capitalization of $684.23M compared with $683.76M for Wave Life Sciences (WVE).
Which stock has performed better over the past year, OLMA or WVE?
OLMA returned -23.95% over the past 12 months, compared with -50.76% for WVE (price return, excluding dividends). Past performance does not predict future results.
Are Olema Pharmaceuticals and Wave Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.